share_log

XORTX Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

XORTX Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

XORTX Therapeutics | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/09/13 16:22

Moomoo AI 已提取核心信息

XORTX Therapeutics has refiled its Management's Discussion and Analysis (MD&A) for both fiscal year 2023 and Q2 2024 following a review by the Alberta Securities Commission. The amended year-end 2023 MD&A now includes a complete definition of Disclosure Controls and Procedures under Internal Controls Over Financial Reporting section.The Q2 2024 MD&A amendments feature additional details on funding allocation for product candidates and estimated costs in the Outlook section. Both documents, restated as of September 12, 2024, maintain their original content except for these specific updates and should be read alongside the corresponding financial statements.XORTX continues to advance two main clinical programs: XRx-008 for ADPKD and XRx-101 for acute kidney injury related to COVID-19 infection. The company also has XRx-225, a pre-clinical program for Type 2 Diabetic Nephropathy, focusing on treatments that target abnormal purine metabolism and xanthine oxidase to reduce uric acid production.
XORTX Therapeutics has refiled its Management's Discussion and Analysis (MD&A) for both fiscal year 2023 and Q2 2024 following a review by the Alberta Securities Commission. The amended year-end 2023 MD&A now includes a complete definition of Disclosure Controls and Procedures under Internal Controls Over Financial Reporting section.The Q2 2024 MD&A amendments feature additional details on funding allocation for product candidates and estimated costs in the Outlook section. Both documents, restated as of September 12, 2024, maintain their original content except for these specific updates and should be read alongside the corresponding financial statements.XORTX continues to advance two main clinical programs: XRx-008 for ADPKD and XRx-101 for acute kidney injury related to COVID-19 infection. The company also has XRx-225, a pre-clinical program for Type 2 Diabetic Nephropathy, focusing on treatments that target abnormal purine metabolism and xanthine oxidase to reduce uric acid production.
XORTX Therapeutics已根据阿尔伯塔证券委员会的审查重新提交了2023财年和2024年第二季度的管理讨论与分析（MD&A）。修订后的2023年年终MD&A现在包括内部控制下披露控制和程序的完整定义。2024年第二季度的MD&A修订中，在前景部分添加了产品候选人的资金分配和估计成本的更多细节。这两份文件于2024年9月12日重新表述，保持其原始内容，除了这些具体更新，并应与相应的基本报表一起阅读。XORTX继续推进两个主要的临床项目：针对ADPKD的XRx-008和与COVID-19感染相关的急性肾损伤的XRx-101。公司还有XRx-225，这是一个针对2型糖尿病肾病的临床前项目，专注于以异常嘌呤代谢和黄嘌呤氧化酶为靶点的治疗，以减少尿酸产生。
XORTX Therapeutics已根据阿尔伯塔证券委员会的审查重新提交了2023财年和2024年第二季度的管理讨论与分析（MD&A）。修订后的2023年年终MD&A现在包括内部控制下披露控制和程序的完整定义。2024年第二季度的MD&A修订中，在前景部分添加了产品候选人的资金分配和估计成本的更多细节。这两份文件于2024年9月12日重新表述，保持其原始内容，除了这些具体更新，并应与相应的基本报表一起阅读。XORTX继续推进两个主要的临床项目：针对ADPKD的XRx-008和与COVID-19感染相关的急性肾损伤的XRx-101。公司还有XRx-225，这是一个针对2型糖尿病肾病的临床前项目，专注于以异常嘌呤代谢和黄嘌呤氧化酶为靶点的治疗，以减少尿酸产生。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Enveric Biosciences
    ENVB
    -- 2.3290
    Renovaro
    RENB
    -- 1.250
    PDS Biotechnology
    PDSB
    -- 1.605
    Salarius Pharmaceuticals
    SLRX
    -- 1.3700
    Eyenovia
    EYEN
    -- 1.835
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！